Targeting MYC-driven lymphoma: lessons learned and future directions.

IF 4.6 Q1 ONCOLOGY 癌症耐药(英文) Pub Date : 2023-04-12 eCollection Date: 2023-01-01 DOI:10.20517/cdr.2022.127
Sandra Martínez-Martín, Marie-Eve Beaulieu, Laura Soucek
{"title":"Targeting MYC-driven lymphoma: lessons learned and future directions.","authors":"Sandra Martínez-Martín, Marie-Eve Beaulieu, Laura Soucek","doi":"10.20517/cdr.2022.127","DOIUrl":null,"url":null,"abstract":"<p><p>MYC plays a central role in tumorigenesis by orchestrating cell proliferation, growth and survival, among other transformation mechanisms. In particular, MYC has often been associated with lymphomagenesis. In fact, MYC overexpressing lymphomas such as high-grade B-cell lymphoma (HGBL) and double expressor diffuse large B-cell lymphomas (DLBCL), are considered addicted to MYC. In such a context, MYC targeting therapies are of special interest, as MYC withdrawal is expected to result in tumor regression. However, whether high MYC levels are always predictive of increased sensitivity to these approaches is not clear yet. Even though no MYC inhibitor has received regulatory approval to date, substantial efforts have been made to investigate avenues to render MYC a druggable target. Here, we summarize the different classes of molecules currently under development, which mostly target MYC indirectly in aggressive B-cell lymphomas, paying special attention to subtypes with MYC/BCL2 or BCL6 translocations or overexpression.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"6 2","pages":"205-222"},"PeriodicalIF":4.6000,"publicationDate":"2023-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344726/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症耐药(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20517/cdr.2022.127","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

MYC plays a central role in tumorigenesis by orchestrating cell proliferation, growth and survival, among other transformation mechanisms. In particular, MYC has often been associated with lymphomagenesis. In fact, MYC overexpressing lymphomas such as high-grade B-cell lymphoma (HGBL) and double expressor diffuse large B-cell lymphomas (DLBCL), are considered addicted to MYC. In such a context, MYC targeting therapies are of special interest, as MYC withdrawal is expected to result in tumor regression. However, whether high MYC levels are always predictive of increased sensitivity to these approaches is not clear yet. Even though no MYC inhibitor has received regulatory approval to date, substantial efforts have been made to investigate avenues to render MYC a druggable target. Here, we summarize the different classes of molecules currently under development, which mostly target MYC indirectly in aggressive B-cell lymphomas, paying special attention to subtypes with MYC/BCL2 or BCL6 translocations or overexpression.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
靶向MYC驱动的淋巴瘤:经验教训和未来方向。
MYC通过协调细胞增殖、生长和存活等转化机制在肿瘤发生中发挥核心作用。特别是,MYC经常与淋巴肿瘤有关。事实上,MYC过表达淋巴瘤,如高级别B细胞淋巴瘤(HGBL)和双表达弥漫性大B细胞淋巴瘤,被认为对MYC上瘾。在这种情况下,MYC靶向治疗特别令人感兴趣,因为MYC退出有望导致肿瘤消退。然而,高MYC水平是否总是预测对这些方法的敏感性增加,目前尚不清楚。尽管迄今为止还没有MYC抑制剂获得监管部门的批准,但已经做出了大量努力来研究使MYC成为药物靶点的途径。在这里,我们总结了目前正在开发的不同类别的分子,它们主要间接靶向侵袭性B细胞淋巴瘤中的MYC,特别关注MYC/BCL2或BCL6易位或过表达的亚型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.60
自引率
0.00%
发文量
0
期刊最新文献
Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma. NFE2L2 and ferroptosis resistance in cancer therapy. The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models. Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies. Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1